A Phase 2 interventional study of GLPG2737 and Placebo in Cystic Fibrosis, sponsored by Galapagos NV. Completed at 9 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-11.
Sponsored by Galapagos NV · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Cystic Fibrosis with a site in Germany — 9 open to participants now, 14 under way, 5 of them phase 3. Cystic Fibrosis · Germany.
Among the 147 studies in Cystic Fibrosis with a site in Germany, this one is the 111th largest by enrollment of the 126 interventional ones that give a count, is one of 14 that started in 2017, is one of 37 in phase 2, and was the 95th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →9 of the 147 studies in Cystic Fibrosis with a site in Germany are open now. Recruiting first, the newest first:
European Breast Cancer Research Association of Surgical Trialists · Sites in Germany
Ages 18+
Research Center Borstel · Sites in Germany
SpliSense Ltd. · Sites in Germany, United States, Czechia and 6 more countries
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18+ · Healthy volunteers
University Hospital of Cologne · Sites in Germany
Ages 18+ · Healthy volunteers
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 47 · Phase 3 62 · Phase 4 5
First in 2000; this study’s year is marked. 14 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 103 across the 126 interventional studies, 104 across the 21 observational. Of the 125 that completed or were terminated, 78 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 8 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Cystic Fibrosis with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT03052283Medizinische Hochschule Brandenburg Theodor FontaneDevelopment and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score) | 2026-12-31 |
| NCT04732910Charite University, Berlin, GermanyModulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators | 2027-03-31 |
| NCT04700358University Hospital of CologneCharacterization of Antibacterial Antibodies in Patients With Cystic Fibrosis | 2027-09-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 147 studies in Cystic Fibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate GLPG2737 administered orally b.i.d. for 28 days to adult male and female subjects with a confirmed diagnosis of cystic fibrosis homozygous for the F508del CFTR mutation and on stable treatment with Orkambi.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GLPG2737 will be provided as capsules for oral use.
Drug: GLPG2737
Placebo will be provided as capsules for oral use.
Drug: Placebo
GLPG2737 oral capsules administered twice daily for 28 days on top of Orkambi.
Placebo oral capsules administered twice daily for 28 days on top of Orkambi.
Change from baseline in sweat chloride concentration compared to placebo
To assess Change from baseline in sweat chloride concentration compared to placebo.
Time frame: Between day 1 pre-morning dose and Day 28.
Change versus placebo in the proportion of subjects with adverse events.
To assess safety and tolerability by the number and percentage of subjects with adverse events.
Time frame: Between Day 1 and 3 weeks after the last dose.
Change from baseline in sweat chloride concentration.
To assess the change from baseline in sweat chloride concentration.
Time frame: From baseline (pre-morning dose on Day 1) through 28 days.
Change in percent predicted forced expiratory volume in 1 second (FEV1).
To assess the change from baseline in percent predicted forced expiratory volume in 1 second (FEV1).
Time frame: From baseline (pre-morning dose on Day 1) through 28 days.
Change in the respiratory domain of the cystic fibrosis questionnaire-revised (CFQ-R).
To assess the change from baseline in the respiratory domain of the cystic fibrosis questionnaire-revised (CFQ-R).
Time frame: From baseline (pre-morning dose on Day 1) through 28 days.
Maximum observed plasma concentration of GLPG2737 (Cmax)
To characterize the PK of GLPG2737 and its active metabolite, ivacaftor, and lumacaftor.
Time frame: Between day 1 pre-dose and day 14.
Area under the plasma concentration-time curve from time zero until 8 hours (AUC0-8h) post-dose calculated by the linear up - logarithmic down trapezoidal rule (on Day 14)
To characterize the PK of GLPG2737 and its active metabolite G1125498 (M4), ivacaftor, and lumacaftor.
Time frame: Between day 1 pre-dose and day 14.
Trough plasma concentration observed at the end of the dosing interval (Ctrough).
To characterize the PK of GLPG2737 and its active metabolite G1125498 (M4), ivacaftor, and lumacaftor.
Time frame: Between day 1 pre-dose and day 28.
Ran from Nov 2017 to primary completion in Apr 2018, 4 months.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 4 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG-2737